Verdora Excellence Alliance
Skip to main content

Verdora Excellence Alliance

Each weekly selection focuses on understanding the factors behind company development, including business models, industry trends, and market context.

KEY FEATURE OF COMPANY RESEARCH

VEA’s weekly selection process focuses on structured company observation, combining multiple perspectives to understand how businesses develop within changing environments. The research approach considers company information, industry conditions, market factors, and long-term development perspectives to provide a broader understanding of selected topics.

CORE FEATURES

Each selection is reviewed through different research perspectives, including:

  • Understanding business models, operational structure, and company development direction.

  • Examining sector trends, competitive conditions, and industry changes.

  • Considering broader economic factors and external conditions influencing business development.

  • Applying structured methods to organize information and compare different perspectives.

Research Focus

Company, industry, and market perspectives are combined to develop a clearer understanding of selected businesses.

Market Insights

Weekly selections provide broader perspectives on business development, industry trends, and changing market environments.

ORION System Weekly Stock Recommendation: PBF Energy ($PBF) – Verdora Excellence Alliance

Many people’s first impression of PBF Energy is often very simple: “A refining stock. It rises when oil prices rise and falls when oil prices fall.” However, this is a common misunderstanding of refining companies. PBF is not an upstream oil producer. It does not make money by: “Extracting a certain number of barrels of crude oil from the ground.” What it actually does is: Buy crude oil → refine it into gasoline, diesel, jet fuel, and other refined products → sell those products into the market. Therefore, what truly matters for PBF is not simply: “Are oil prices high or low?” The more important question is: How much does the company pay for crude oil, and how much can it sell the refined products for afterward? The difference between those two prices is one of the most important profit drivers in refining: Refining Margin. As of September 28, 2026, the most important reason to study PBF is precisely this: The refining industry’s supply-demand environment is improving, while the company’s own balance sheet is undergoing rapid recovery. Latest Financial Results: Net Income Rebounded From Loss to $915 Million In Q2 2026, PBF generated revenue of: $11.678 billion. Operating income reached: $1.272 billion. Compared with only: $43 million in the same period last year. Net income reached: $915 million. Net income attributable to PBF Energy: $906.4 million. Diluted EPS reached: $7.54. However, one important point must be clarified: This $7.54 EPS should not be interpreted entirely as normal refining profitability. Because Q2 included several special items, with the most important being: Insurance proceeds related to the Martinez refinery fire. These special items contributed approximately: $159.8 million after tax to net income, equivalent to approximately: $1.32 per share. After excluding these special items, PBF’s Q2 adjusted Fully-Converted net income still reached: $753.1 million. Adjusted EPS: $6.22. Therefore, even after removing the insurance benefit, Q2 still represented a very strong operating performance. The Most Important Point: The Company Was Still Losing Money One Year Earlier In Q2 2025: PBF’s adjusted Fully-Converted net loss was: $118.5 million. Adjusted loss per share: $1.03. By Q2 2026: -$1.03 per share had become: +$6.22 per share. This…

Read More »

ORION System Weekly Stock Recommendation: Amgen ($AMGN) – Verdora Excellence Alliance

Many people’s first impression of Amgen is: “A long-established large biotechnology company.” Unlike Moderna, it does not have an mRNA-focused growth story. Unlike smaller biotechnology companies, where one Phase 3 result can dramatically change the company’s valuation. But this is exactly where AMGN is often underestimated. Amgen’s real strength is not: Betting on a single drug. Instead, the company combines: Mature product cash flow + multiple fast-growing medicines + oncology pipeline + cardiovascular business + rare disease assets + next-generation obesity treatment opportunities. Therefore, when analyzing AMGN on September 21, the most important question is not: “Will the next drug succeed?” The real question is: Can Amgen use its already substantial cash flow to successfully transition from legacy products to the next generation of major growth medicines? First Look at the Latest Results: Quarterly Revenue Surpasses $10 Billion In Q2 2026, Amgen generated total revenue of: $10.1 billion. Up: 10% year over year. Product sales increased: 9%. Growth was mainly driven by: Higher sales volume. GAAP EPS increased from: $2.65 in the same period last year to: $4.37. A year-over-year increase of: 65%. Non-GAAP EPS reached: $6.29. An increase of: 4%. More importantly, Q2 free cash flow reached: $3.5 billion. Compared with: $1.9 billion in the same period last year. This highlights one of the biggest differences between Amgen and many biotechnology companies still operating in the clinical development stage: Amgen is not simply spending cash while waiting for future products. The company already has strong current earnings power. And it can use that cash flow to invest in the next generation of medicines. However, $10.1 Billion in Revenue Is Not the Most Important Number The more important development is: Amgen is undergoing a transformation in its product portfolio. In Q2, the company’s six key growth drivers increased by: 26% year over year. These products already represented nearly: 70% of quarterly product sales. At the same time: 22 products achieved double-digit growth. Based on Q2 sales performance annualized: 17 products have already reached more than $1 billion in annual sales. This is highly significant. Because it shows Amgen is no longer: A large biotechnology company supported by only one or…

Read More »